| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Full Paper |
1 Department of Radiation Oncology and Diagnostic Imaging, University of Turin, Turin and 2 Medical Physics Division, S. Giovanni Battista Hospital, Via Genova 3, 10126 Turin, Italy
Correspondence: Dr G L Sannazzari, Department of Radiation Oncology and Diagnostic Imaging, S. Giovanni Battista Hospital, Via Genova 3, 10126 Turin, Italy
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Since patients may be treated radically either by surgery or radiation, with equivalent disease-free and overall survival rates, the choice of treatment modality is often based on a comparison of treatment related morbidity [3, 4].
Progress in medical imaging, as well as computer hardware and software developments, has led to improvements in the delineation and modeling of tumour volumes for radiation therapy, depending on the clinical stage of the disease (prostate gland and a variable portion of the seminal vesicles). These volumes, defined by 5 mm thick axial CT slices [1], are the basis upon which conformal treatment plans using three-dimensional (3D) treatment planning systems are designed. However, while CT easily recognizes the upper prostate and seminal vesicles, the lower extent of the gland is difficult to distinguish from adjacent normal structures, i.e. urogenital diaphgram, because of small CT numbers [5]. Since MRI yields more contrast than CT when differentiating the prostate gland from the periprostatic soft tissues, as well as allowing more precise delineation of normal critical structures and more accurate definition of treatment volumes. Diagnostic information available from MRI can be incorporated into that of CT [6, 7]. This integration of complementary information from two or more separate imaging studies into a single consistent imaging study is called "image fusion". This technique can better enable the radiation oncologist and medical physicist to design and execute a successful course of therapy and more closely follow the progress of the patient after therapy.
However, imaging data from MRI introduces some geometric distorsion because all magnetic fields possess inhomogeneities of the main field and non-linearities of magnetic field gradients and eddy current effects. In general, system distortion is particularly important for larger fields of view (FOVs) as this distorsion tends to increase with increasing distance from the centre of the magnet [8]. Also MRI does not provide the necessary geometric accuracy and physical information required in CT based 3D treatment planning systems, such as electron density of body tissues. Nor can MR image complex bone/air heterogeneity. This information is essential for patient dose calculation and for designing compensators and modulators to shape the beam profile. Therefore, the unique information provided by MRI studies must be registered to, and then integrated with, the treatment planning CT data set.
A variety of quantitative methods have been developed to determine transformation parameters, including point matching, line or curve matching, surface matching and volume matching.
This paper evaluates the possible contribution of MRI images in accurately defining clinical target volume (CTV) (prostate and seminal vesicles), by giving the necessary information for computerized delineation leading to image fusion.
This study is based on the evaluation of the results achieved with CTMRI image fusion in a group of patients suffering from localized prostate carcinoma, and is an effort in analyzing and rationalizing the use of this methodology for better treatment planning in radiation oncology.
| Material and methods |
|---|
|
|
|---|
For all patients, diagnosis was based on prostate specific antigen (PSA) levels and biopsy. Patient age ranged from 61 years to 76 years (median 71 years), and palpation T stage ranged from T1a to T2b. The median pre-treatment PSA was 12.6 ng ml-1 (range 7.614.8 ng ml-1). Gleason Score ranged from 3 to 9 (median 6).
To ensure that patients could be positioned in a reproducible fashion for planning and treatment, individualized thermoplastic casts were produced for each patient. Each patient underwent CT and MRI in the planned treatment position within the immobilization device from level L5S1 to 10 mm caudal to the ischial tuberosities. CT and MR images were 3 mm thick and had a 3 mm interval, these conditions being necessary for correct image fusion. Pelvic MRI was taken with a 1 T scanner, using phase array multicoil. In order to minimize MRI geometric distortion, patients were positioned to set the CTV at the magnet centre.
Image fusion was obtained through transversal T2 weighted images (TR/TE= 4600 ms/100 ms). The contours of CTV and critical organs and structures, such as rectum, bladder and femoral heads, were later delineated by the same radiation oncologist on the acquired CT and MR images (Figure 1
). Moreover, in 3D treatment planning it is necessary to take into account uncertainties in tumour delineation, organ motion and day to day patient positioning. To compensate for these uncertainties, additional safety margins have usually been added to the CTV to shape the planning target volume (PTV), extending into surrounding normal tissue to decrease the risk of marginal tumour miss. Therefore, PTV included the entire prostate and seminal vesicles plus 1.0 cm margins, except at the prostaterectum interface where a 0.6 cm margin was used to decrease the risk of rectal toxicity.
|
| Results |
|---|
|
|
|---|
|
|
Measures taken on the superiorinferior direction show a 5 mm mean overestimation of CT compared with MRI. The linear regression line shows similar values for small sections of the prostate, whereas a noticeable difference is registered for larger sections of the gland (78 mm discrepancy at dimensions of 60 mm) (Figure 4
).
|
|
The dosevolume histogram resulting from CTMRI comparison shows that it is possible to spare approximately 10% of rectal volume and approximately 5% of bladder and femoral head volumes, by delineating CTV on MRI acquired images. All in all, comparison between the two methods only shows small differences, and it is important to evaluate its clinical yield, taking into account the closeness between the prostate, rectum and bladder.
| Conclusion |
|---|
|
|
|---|
Our study showed that the volume measured through CT, including prostate and seminal vesicles, was 34% greater than the same volume acquired through MRI. Kagawa et al [11], in a similar study on 22 patients, proved a mean increase in CT acquired prostate volume with or without seminal vesicles of 27% compared with MRI. Studies conducted by Rasch et al [12] and by Roach et al [13], where the volume only included the prostate, proved an increase of 43% and 32%, respectively, on CT acquired measurements compared with MRI. In our study, mean absolute values are higher than reported by other authors (Table 1
). This may be due to our delineation of volume, which always included the prostate capsule and seminal vesicles. Some authors [1416] evaluated MRI prostate volume before radical prostatectomy compared with surgical specimens. Results from these studies indicate that MRI accuracy consistently underestimated prostate volume.
|
A mean forward shift of 5 mm in MRI-acquired CTV images was noted, probably due to the different degree of rectal and bladder filling.
The comparison of dosevolume histograms in a patient presenting morphological and volumetric characteristics similar to mean values of all analyzed patients, showed that it is possible to spare approximately 10% of the rectal volume included in the radiation field and approximately 5% of bladder and femoral head volumes.
This study has identified both where and why the CT imaged prostate is larger than the MR imaged prostate. These findings may help radiation oncologists in target identification and regarding normal structures adjacent to the prostate, when the latter is imaged by CT for treatment planning. An accurate definition of target volume is the base of overall treatment procedure. More precise targeting may result not only in improved disease free survival and post-treatment biopsy but also in decreased morbidity by reducing radiation induced damage to normal tissues.
Anatomical organ motion and patient positioning (set-up) are an especially large barrier to conformal radiation therapy. However, considering the excellent outcomes of prostate cancer treatment with CT-based target identification and low treatment related toxicity, we are still reluctant to reduce CTV to that identified by MRI until we can control organ motion during each radiotherapy session. Both accurate targeting and adequate control of organ motion are crucial to optimize the CTV.
Received for publication August 3, 2001. Revision received November 19, 2001. Accepted for publication January 8, 2002.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A S N Jackson, S A Reinsberg, S A Sohaib, E M Charles-Edwards, S A Mangar, C P South, M O Leach, and D P Dearnaley Distortion-corrected T2 weighted MRI: a novel approach to prostate radiotherapy planning Br. J. Radiol., November 1, 2007; 80(959): 926 - 933. [Abstract] [Full Text] [PDF] |
||||
![]() |
V S Khoo and D L Joon New developments in MRI for target volume delineation in radiotherapy Br. J. Radiol., September 1, 2006; 79(Special_Issue_1): S2 - S15. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Charnley, A Morgan, E Thomas, S Wilson, S Bacon, D Wilson, and D Bottomley The use of CT-MR image registration to define target volumes in pelvic radiotherapy in the presence of bilateral hip replacements Br. J. Radiol., July 1, 2005; 78(931): 634 - 636. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| BJR | DMFR | IMAGING | ALL BIR JOURNALS |